This Power Buy is ready for whichever vaccines work

Article Excerpt

Thermo Fisher keeps soaring for our readers—it’s up 39.4% since we first recommended it in our May 2020 issue at $325.83. Thermo Fisher doesn’t make vaccines. But it does provide key equipment that will be needed regardless of whose vaccines succeed. Thermo Fisher is a Power Buy for our Power Growth Investors. THERMO FISHER SCIENTIFIC INC. $454.18, is a buy. Your shares (New York symbol TMO; TSINetwork Rating: Average) (www.thermofisher.com; Shares outstanding: 396.3 million; Market cap: $189.8 billion; Dividend yield: 0.2%) let you tap this leading manufacturer of scientific instruments, laboratory equipment, diagnostic consumables, and life science reagent chemicals. Thermo Fisher also sells a full range of medical refrigerators and freezers. This includes the ultracold freezers that Pfizer and BioNTech will need if their recently announced vaccine candidate wins approval. That particular vaccine must be stored at minus 70C. Moderna’s vaccine only needs to be stored at minus 20C. Other vaccines under development may just require simple refrigeration. Either way, Thermo Fisher offers…

You are trying to access subscriber-only content.

To read this article, you may subscribe or sign in.
If you are already a subscriber, log in here.

If you wish to become a subscriber, click here. Or you may enjoy access to all our publications when you become a Member of Pat McKeough's Inner Circle Pro.